Warning Letter — LyfeUnit / www.lyfeunit.com
The FDA issued a warning letter to LyfeUnit regarding the marketing and distribution of products via their website that the agency deems to be unapproved new drugs.
This affects LyfeUnit and its internal departments responsible for regulatory compliance, marketing, and digital distribution operations.
The issuance of a CDER warning letter indicates that the FDA has identified significant violations of the Federal Food, Drug, and Cosmetic Act involving the sale of products with therapeutic claims without required drug approvals. This suggests an enforcement focus on e-commerce platforms that may be operating outside of established drug regulatory frameworks, potentially leading to forced product removal or further legal enforcement if not remediated.
Firms operating digital health or wellness platforms should audit all online product listings to ensure marketing claims do not inadvertently classify consumer goods as unapproved drugs. Immediate cessation of any claims suggesting therapeutic or diagnostic capabilities for unvetted products is necessary to achieve compliance.
FDA Warning Letter issued to: LyfeUnit / www.lyfeunit.com. 06/23/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lyfeunit-wwwlyfeunitcom-725156-06232026
Open in openFDA / FDA.gov